GeneDx stock reaffirmed at Overweight by Piper Sandler amid selloff

Piper Sandler reiterated an Overweight on GeneDx (NASDAQ:WGS) with a $130 price target, arguing the stock’s drop from about $135 to $70 already prices in a possible guidance miss. The firm still sees nearly 40% revenue growth over the last twelve months and says the stock trades at less than 3x 2027 sales, but investors remain focused on first-quarter results due in 13 days on May 4. Other analysts remain constructive, though BTIG cut its target to $170 from $200 and Natera’s new rare-disease sequencing assay adds competitive pressure.

Analysis

The most important second-order effect is that the capital commitment to Anthropic is less about near-term economics and more about locking in a strategic AI distribution layer before model capabilities commoditize. That should be incrementally positive for AMZN because it strengthens AWS’s position as the default infrastructure and procurement layer for enterprise AI spend, even if the direct monetization of Anthropic remains opaque. The market is likely underestimating how much this reduces the odds of customers routing frontier-model workloads through competing clouds over the next 12-24 months.

For WGS, the setup is a classic expectation reset trade: the stock has already de-rated as if management will miss badly, so the bar for a positive reaction is not strong results but merely removal of the overhang around the guidance frame. The key nuance is that this business is sensitive to volume inflections more than headline revenue, which means a modest guide-down can still coexist with a constructive multi-quarter trajectory if mix and reimbursement stay intact. The risk is that any hint of slower exome/genome adoption changes the market’s perception of TAM durability, which would compress the multiple further despite the stock already pricing in a lot of bad news.

NTRA is the cleaner competitive loser on a relative basis if investors conclude the rare-disease sequencing market is becoming more crowded, because the winner is increasingly the platform with the deepest interpretive dataset rather than the newest assay. That said, the near-term damage to WGS from new competition may be less than feared if physician adoption is driven by turnaround, workflow integration, and evidence-generation rather than test parity. The contrarian view is that the selloff in WGS may be overdone precisely because the market is conflating competitive noise with a permanent demand impairment.

The catalyst window is tight: WGS earnings over the next two weeks matters far more than the AI headline, while the Anthropic deal is a multi-quarter strategic signal rather than a tradable near-term P&L event. If WGS guides even modestly below prior expectations but reaffirms volume resilience, the stock could re-rate quickly because positioning appears washed out. If guidance is materially cut, downside could extend another 15-25% before value buyers step in.

Key Decisions for Investors

• WGS: initiate a small pre-earnings long into the May 4 print, sized for a 10-15% upside reaction if guidance uncertainty clears; add only if management preserves volume trajectory and refrains from signaling structural demand weakness.
• WGS: pair long WGS / short NTRA for 1-3 month horizon to express relative-share gains from dataset advantage and valuation compression in the incumbent; cut if NTRA demonstrates faster adoption or WGS commentary weakens TAM confidence.
• AMZN: buy on pullbacks over the next 1-3 months as a strategic AI-infrastructure compounder; the risk/reward is skewed to a slow-burn multiple support rather than an immediate earnings pop, with downside limited unless capital intensity escalates materially.
• Optionality on WGS: consider a call spread into earnings rather than outright stock if you want event convexity with defined downside; the best case is a sharp rerating on guidance clarity, while the worst case remains a further washout.
• If WGS gaps down on a guide cut but volumes remain intact, be prepared to scale in aggressively on the post-print weakness rather than chasing pre-earnings strength.